Medigene AG: Medigene Licenses Co-stimulator to Enhance TCR Therapies for Solid Tumors

Medigene AG: Medigene Licenses Co-stimulator to Enhance TCR Therapies for Solid Tumors Business news for the stock market Planegg (04.01.2019) - -A mechanism expected to overcome checkpoint blockade in T cells Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced that it has entered into an exclusive license agreement with Helmholtz Zentrum Munich (HMGU), a German public research institution operating in the field of environmental health, for a chimeric co-stimulatory receptor which is a fusion protein of PD-1 and 4-1BB. Medigene intends to explore applying the receptor in co [...]


read full post from firmenpresse

(164896 Posts)

Leave a Reply